Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 studyEzra E.W. Cohen, Signe Friesland, Myung‐Ju Ahn et al.|The Lancet|2018Cited by 1.7k
Afatinib vs Placebo as Adjuvant Therapy After Chemoradiotherapy in Squamous Cell Carcinoma of the Head and NeckBarbara Burtness, Robert I. Haddad, José Dinis et al.|JAMA Oncology|2019Cited by 43
Atezolizumab in High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and NeckRobert I. Haddad, Deborah Jean Lee Wong, Jérôme Fayette et al.|JAMA|2025Cited by 42